RBC Capital Maintains Outperform on Bio-Rad Laboratories, Lowers Price Target to $480
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Conor McNamara has maintained an Outperform rating on Bio-Rad Laboratories (NYSE:BIO) but lowered the price target from $484 to $480.

February 16, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital has maintained an Outperform rating on Bio-Rad Laboratories but reduced the price target from $484 to $480.
The adjustment in price target by RBC Capital reflects a slight change in valuation perspective, likely due to updated financial analysis or market conditions. However, maintaining the Outperform rating indicates a continued positive outlook on the company's performance. The minor reduction in price target is not expected to have a significant impact on the stock's short-term movement, as the overall recommendation remains positive.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100